{"entity":{"id":"nct04947189","kind":"trial","name":"Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer","aka":["4CAST"],"tldr":"A phase 1/2 trial of dexamethasone and docetaxel in triple-negative breast cancer, run by St Vincent's Hospital, Sydney, now recruiting.","summary":"Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer is a phase 1/2, interventional study registered as NCT04947189 by St Vincent's Hospital, Sydney, with a registry enrolment figure of 65 participants, started 2022-11-01 and due to reach its primary completion in 2026-07. Interventions recorded: Seviteronel-D (Seivteronel in combination with dexamethasone); Docetaxel. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \", IHC 3+ or in situ hybridisation (ISH) positive according to standard ASCO/CAP guidelines or triple-negative breast cancer, i\". Sites: Australia. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04947189","url":"https://clinicaltrials.gov/study/NCT04947189"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["dexamethasone","docetaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04947189","phase":"1/2","setting":"4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer","sponsor":"St Vincent's Hospital, Sydney","enrolled":65,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04947189/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}